Theravance Biopharma, Inc. (TBPH) Key Metrics
TBPH valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $884.2M
- Enterprise value
- $535.1M
- P/E (TTM)
- 16.4
- Forward P/E
- 9.7
- PEG ratio
- —
- Price / sales
- 8.5 10-yr median 15.7
- Price / book
- 3.1 10-yr median 3.1
- EV / EBITDA
- 8.6
- Dividend yield
- —
- Beta
- 0.24
TBPH key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsTBPH valuation Price multiples at each fiscal year-end price.
TBPH returns How much profit the business earns on the capital it uses.
TBPH per-share figures Results divided by the shares outstanding at year-end.
TBPH financial health Debt, liquidity and how easily interest is covered.
TBPH efficiency & capital use Working capital cycle and where the cash goes.
TBPH valuation history
TBPH returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
TBPH debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
TBPH cash returned to shareholders
TBPH price vs earnings per share
TBPH key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $963.7M | $459.7M | $621.6M | $825.7M | $767.5M | $1.11B | $1.44B | $1.38B | $1.46B | $1.43B |
| Enterprise value | $723.8M | $421.1M | $568.3M | $550.4M | $1.26B | $1.49B | $1.67B | $1.33B | $1.34B | $1.15B |
| P/E ratio | 9.1 | — | — | 0.9 | — | — | — | — | — | — |
| Price / sales | 9.0 | 7.1 | 10.8 | 16.1 | 13.9 | 15.4 | 19.6 | 22.9 | 94.9 | 29.3 |
| Price / book | 3.2 | 2.6 | 2.9 | 1.9 | — | — | — | — | 12.7 | 4.1 |
| Price / free cash flow | 4.0 | — | — | — | — | — | — | — | — | — |
| Price / operating cash flow | 4.0 | — | — | — | — | — | — | — | — | — |
| EV / sales | 6.7 | 6.5 | 9.9 | 10.7 | 22.8 | 20.8 | 22.7 | 22.0 | 86.8 | 23.6 |
| EV / EBITDA | 5.3 | — | — | — | — | — | — | — | — | — |
| EV / free cash flow | 3.0 | — | — | — | — | — | — | — | — | — |
| Earnings yield | 11.0% | −12.3% | −8.9% | 105.6% | −26.0% | −25.1% | −16.4% | −15.6% | −19.5% | −13.4% |
| Free cash flow yield | 24.7% | −2.6% | −4.7% | −22.7% | −27.5% | −23.2% | −16.8% | −8.7% | −13.9% | −7.1% |
| Dividend yield | — | — | — | 0.1% | — | 34.8% | — | — | 0.0% | 0.0% |
| Shareholder yield (dividends + buybacks) | 0.4% | 0.7% | 32.1% | 16.1% | 1.2% | 35.6% | 0.2% | 0.7% | 0.6% | 0.3% |
| Share price at fiscal year-end | $18.71 | $9.41 | $11.24 | $11.22 | $11.05 | $17.77 | $25.89 | $25.59 | $27.89 | $31.88 |
| Per share | ||||||||||
| Revenue per share | $2.09 | $1.32 | $1.04 | $0.70 | $0.80 | $1.15 | $1.32 | $1.12 | $0.29 | $1.09 |
| Earnings per share | $2.06 | −$1.15 | −$1.00 | $11.85 | −$2.87 | −$4.46 | −$4.25 | −$3.99 | −$5.45 | −$4.26 |
| Operating cash flow per share | $4.63 | −$0.24 | −$0.49 | −$2.54 | −$2.99 | −$4.02 | −$4.28 | −$2.09 | −$3.84 | −$2.21 |
| Free cash flow per share | $4.63 | −$0.24 | −$0.53 | −$2.55 | −$3.04 | −$4.12 | −$4.34 | −$2.23 | −$3.89 | −$2.26 |
| Cash per share | $6.12 | $1.81 | $1.85 | $4.45 | $2.50 | $4.70 | $5.05 | $9.36 | $6.66 | $11.21 |
| Book value per share | $5.76 | $3.59 | $3.85 | $6.00 | −$4.87 | −$4.87 | −$4.03 | −$0.96 | $2.20 | $7.83 |
| Tangible book value per share | $5.76 | $3.59 | $3.85 | $6.00 | −$4.87 | −$4.87 | −$4.03 | −$0.96 | $2.20 | $7.83 |
| Dividends per share | — | — | — | $0.01 | — | $6.18 | — | — | $0.00 | $0.00 |
| Capex per share | $0.00 | $0.01 | $0.04 | $0.01 | $0.05 | $0.11 | $0.06 | $0.13 | $0.05 | $0.05 |
| Debt per share | $1.47 | $1.02 | $0.89 | $0.71 | $9.64 | $10.85 | $9.18 | $8.42 | $4.27 | $4.98 |
| Shares outstanding | 51.5M | 48.8M | 55.3M | 73.6M | 69.5M | 62.3M | 55.6M | 54.0M | 52.4M | 44.7M |
| Change in shares outstanding | +5.4% | −11.7% | −24.9% | +5.9% | +11.4% | +12.1% | +3.0% | +3.1% | +17.1% | +30.9% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 44.8% | −29.0% | −16.9% | — | — | — | — | — | −122.6% | −64.3% |
| Return on invested capital (ROIC) | −11.2% | −25.0% | −27.1% | −44.8% | −171.8% | −550.5% | — | — | — | −78.0% |
| Return on assets (ROA) | 25.2% | −15.3% | −11.2% | 177.6% | −47.3% | −63.3% | −48.8% | −43.0% | −52.8% | −40.6% |
| Return on tangible assets | 21.8% | −15.9% | −14.4% | 143.6% | −53.2% | −59.3% | −57.8% | −38.5% | −64.7% | −29.8% |
| Free cash flow margin | 221.9% | −18.4% | −51.3% | −365.3% | −382.0% | −357.7% | −328.8% | −199.0% | — | −207.9% |
| Income quality (OCF / net income) | 2.25 | — | — | −0.21 | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $75.5M | $49.8M | $49.2M | $52.2M | $669.5M | $676.3M | $510.5M | $454.4M | $223.7M | $222.7M |
| Cash & short-term investments | $315.4M | $88.3M | $102.4M | $327.5M | $173.5M | $292.9M | $280.8M | $505.3M | $348.6M | $501.1M |
| Net debt | −$239.9M | −$38.5M | −$53.3M | −$275.3M | $496.1M | $383.3M | $229.7M | −$50.9M | −$124.8M | −$278.4M |
| Debt / equity | 0.25 | 0.28 | 0.23 | 0.12 | — | — | — | — | 1.94 | 0.64 |
| Debt / assets | 0.16 | 0.14 | 0.13 | 0.09 | 1.79 | 1.44 | 1.25 | 0.81 | 0.51 | 0.35 |
| Net debt / EBITDA | −1.75 | — | — | — | — | — | — | — | — | — |
| Current ratio | 10.93 | 5.02 | 5.39 | 12.31 | 4.26 | 3.18 | 3.03 | 5.41 | 6.05 | 10.73 |
| Quick ratio | 10.93 | 7.16 | 5.39 | 12.26 | 4.09 | 3.02 | 3.03 | 5.41 | 5.79 | 10.48 |
| Interest coverage | -5.4 | -18.4 | -23.8 | -14.4 | -30.2 | -34.8 | -7.9 | -22.8 | -30.4 | -128.5 |
| Working capital | $380.2M | $129.0M | $108.8M | $324.7M | $191.3M | $269.8M | $226.8M | $434.3M | $316.2M | $479.2M |
| Invested capital | $56.9M | $137.0M | $159.7M | $166.5M | $157.5M | $79.6M | $5.9M | −$102.5M | −$9.6M | $71.8M |
| Tangible asset value | $296.7M | $175.5M | $213.0M | $441.8M | −$338.6M | −$303.8M | −$223.8M | −$51.6M | $115.2M | $350.2M |
| Net current asset value | $229.6M | −$17.5M | −$35.5M | $187.9M | −$463.5M | −$379.5M | −$294.2M | −$79.0M | $52.5M | $239.5M |
| Graham number | $16.32 | — | — | $40.01 | — | — | — | — | — | — |
| Graham net-net per share | $3.85 | −$1.50 | −$0.97 | $2.38 | −$7.08 | −$6.70 | −$5.64 | −$1.83 | $0.69 | $5.03 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | $802,000 | — | $385.1M | — | — | $0 | $0 |
| Share buybacks (net) | $4.0M | $3.1M | $199.6M | $132.3M | $9.1M | $9.7M | $3.2M | $9.8M | $8.6M | $3.9M |
| Dividend payout ratio | — | — | — | 0.1% | — | — | — | — | — | — |
| Dividends + buybacks / free cash flow | 1.7% | — | — | — | — | — | — | — | — | — |
| Capex / revenue | 0.0% | 0.5% | 4.3% | 1.1% | 6.2% | 9.2% | 4.3% | 12.0% | 15.6% | 4.4% |
| Capex / operating cash flow | 0.0% | — | — | — | — | — | — | — | — | — |
| Capex / depreciation | 0.01 | 0.09 | 0.58 | 0.08 | 0.40 | 0.73 | 0.51 | 2.29 | 0.60 | 0.68 |
| Stock-based compensation / revenue | 17.2% | 33.2% | 44.2% | 77.4% | 112.2% | 87.6% | 82.3% | 85.0% | 319.4% | 84.6% |
| R&D / revenue | 34.8% | 59.1% | 80.7% | 136.5% | 364.4% | 363.2% | 298.6% | 333.5% | 1,130.2% | 291.3% |
| SG&A / revenue | 68.5% | 100.8% | 113.8% | 115.0% | 179.5% | 151.2% | 144.5% | 160.8% | 621.3% | 173.7% |
| Efficiency | ||||||||||
| Days sales outstanding | 278.5 | 243.5 | 108.9 | 264.4 | 419.9 | 305.4 | 152.2 | 53.8 | 192.0 | 173.4 |
| Days of inventory on hand | — | -332.2 | 6.8 | 33.9 | 28.9 | 14.2 | 0.0 | 4,295.8 | 879.2 | 1,401.5 |
| Days payables outstanding | 159.2 | 18.3 | 13.8 | 13.4 | 9.3 | 8.1 | 11.5 | 3,816.4 | 231.7 | 1,295.1 |
| Cash conversion cycle (days) | 119.3 | -106.9 | 101.8 | 284.8 | 439.5 | 311.6 | 140.8 | 533.1 | 839.4 | 279.9 |
| Receivables turnover | 1.31 | 1.50 | 3.35 | 1.38 | 0.87 | 1.20 | 2.40 | 6.79 | 1.90 | 2.10 |
| Payables turnover | 2.29 | 19.99 | 26.39 | 27.25 | 39.23 | 45.25 | 31.81 | 0.10 | 1.58 | 0.28 |
| Inventory turnover | — | — | 53.70 | 10.78 | 12.65 | 25.62 | 219,248,000.00 | 0.08 | 0.42 | 0.26 |
| Asset turnover | 0.26 | 0.17 | 0.12 | 0.10 | 0.13 | 0.16 | 0.15 | 0.12 | 0.03 | 0.10 |
| Average receivables | $82.0M | $43.0M | $17.1M | $37.2M | $63.6M | $60.1M | $30.6M | $8.9M | $8.1M | $23.1M |
| Average payables | $2.4M | $1.9M | $1.5M | $2.3M | $4.9M | $5.8M | $6.9M | $7.5M | $3.8M | $10.3M |
| Average inventory | — | −$34.3M | $756,500 | $5.9M | $15.3M | $10.2M | $1 | $8.4M | $14.5M | $11.1M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from TBPH's annual financial statements (latest annual report filed March 23, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
TBPH valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Theravance Biopharma traded at 9.1 times earnings. Based on the latest twelve months, the trailing P/E is 16.4 and the forward P/E is 9.7. Theravance Biopharma earned a return on equity of 44.8% and a return on invested capital of −11.2% in fiscal 2025. It ended the year with $75.5 million of debt and $315.4 million in cash and short-term investments, a net cash position of $239.9 million. It returned $4.0 million to shareholders: $0 in dividends and $4.0 million in share buybacks, 2% of free cash flow. The share count rose 15.2% from 44.7M to 51.5M over 9 years.
See the TBPH income statement, the TBPH chart for price history, or the TBPH stock overview for the latest quote and news.
TBPH key metrics FAQ
What is Theravance Biopharma's P/E ratio?
Theravance Biopharma's trailing P/E ratio is 16.4 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 9.7. At the end of fiscal 2025 it was 9.1.
What is Theravance Biopharma's EV/EBITDA?
Theravance Biopharma's enterprise value was 5.3 times EBITDA at the end of fiscal 2025 (enterprise value $723.8 million, EBITDA $137.2 million); the current EV/EBITDA is 8.6.
What is Theravance Biopharma's return on equity?
Theravance Biopharma's return on equity (ROE) was 44.8% in fiscal 2025: net income of $105.9 million on average shareholders' equity of $236.1 million.
What is Theravance Biopharma's ROIC?
Theravance Biopharma's return on invested capital was −11.2% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Theravance Biopharma have?
Theravance Biopharma had total debt of $75.5 million at the end of fiscal 2025, a debt-to-equity ratio of 0.25 and more cash than debt.
Does Theravance Biopharma buy back its shares?
Yes. Theravance Biopharma spent $4.0 million on net share repurchases in fiscal 2025 Shares outstanding changed +5.4% over the year, to 51.5M..
What is Theravance Biopharma's free cash flow yield?
Theravance Biopharma generated $238.5 million of free cash flow in fiscal 2025, a free cash flow yield of 24.7% on its market value at year-end ($963.7 million).
What is Theravance Biopharma's current ratio?
Theravance Biopharma's current ratio was 10.93 at the end of fiscal 2025: current assets were 10.93 times current liabilities.